$591 | SAVE $104 | Single User
$1186 | SAVE $209 | Global License

Physician Views: What role will device development play in the future GLP-1 agonist market?
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 07 Mar 2014 | 104 | In Stock
Related Topics: AstraZeneca , GlaxoSmithKline , Lilly

Introduction

Scope



Positioned frequently as a transitional diabetes therapy between oral agents and insulin – and like insulin requiring administration via an injection – device development appears set to play a key role in the evolution of the GLP-1 agonist market over the next 12 to 18 months.


Other factors – primarily the launch of additional products such as Eli Lilly's dulaglutide, GlaxoSmithKline's albiglutide and the continued global roll-out of Sanofi's Lyxumia, coupled with the scope that this will provide payers to extract greater discounting and rebates – will also play a role in market development.


Nevertheless, AstraZeneca is hoping that a new pen device will boost sales of its GLP-1 agonist Bydureon, while familiarity with Novo Nordisk's devices (not to mention the Danish company's experience with such technologies) has at least played some role in establishing its Victoza brand as the market leader. Furthermore, Eli Lilly is looking to bring dulaglutide to market in an auto-injector device, use of which precludes the patient to touch or even see the needle – see Spotlight On: Too little too late? – Intensifying competition and pricing pressure likely to limit AstraZeneca's progress via new Bydureon device.


Initial development of the GLP-1 agonist market has at least been partially shaped by device design. There is a broad perception, for example, that the commercial uptake of Bydureon has been limited by both the requirement of patients to reconstitute the drug prior to self administration, which then occurs with a needle that is larger than that used with Novo Nordisk's Victoza device. Hence ongoing efforts by AstraZeneca (and previous partner Bristol-Myers Squibb) to develop a more patient-friendly device.


Puchase Reasons


To gain a better understanding of the role that devices play/will play in the GLP-1 agonist market, FirstWord is polling US and EU5 based endocrinologists with the following five questions:


  • To what extent they believe that the injectable delivery of GLP-1 agonist products has acted to reduce usage and/or patient preference towards this drug class as a whole?

  • What advantage they perceive would be provided by an auto-injector pen device for a GLP-1 agonist therapy where the needle is not seen/touched by the patient?

  • Whether the Bydureon device has limited their uptake of this product relative to other factors?

  • By what percentage they expect the availability of a new Bydureon device to increase their usage of this drug?

  • How advances in delivery devices will likely have in dictating prescription trends moving forward?
  • Table of Contents
    for Physician Views: What role will device development play in the future GLP-1 agonist market? [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    104 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    SAVE 15% today! Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: What role will device development play in the future GLP-1 agonist market? [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...